Contact
Please use this form to send email to PR contact of this press release:
Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market
TO:
Please use this form to send email to PR contact of this press release:
Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market
TO: